Abstract: The invention relates to compounds of formula (I) as follows: (I) wherein X1 and X2, identical or different, are NR5 or a sulfur atom, Y is a group (C1-C10)alkanediyl, Ar1 and Ar2, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C1-C6) alkyl, —OR1, —NR1R2 and —COOR3? with R1 and R2, independently of each other, are a hydrogen atom, a (C-1-C6) alkyl group or a —COR3 group, R3 and R4? independently of each other, are a hydrogen atom or a (C1-C6) alkyl group, and R5 is a hydrogen atom or a (C1-C6)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically hinds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Abstract: The invention relates to antibodies against extracellular epitopes of human Transient Receptor Potential Vanilloid 6 (TRPV6) channel protein, in particular antibodies which modulate TRPV6 channel activity on the plasma membrane and thereby trigger apoptosis of cancer cells expressing TRPV6. The invention relates also to the use of said antibodies for the diagnosis, prognosis and treatment of diseases involving TRPV6 channels, in particular diseases associated with TRPV6-expression such as cancers. The invention further relates to peptide antigens from human TRPV6 protein useful for the production of said antibodies.

Abstract: The present invention relates to the treatment of sensory neuropathy induced by a marine neurotoxic poisoning. The invention further encompasses an in vitro method for producing a neuro-cutaneous model allowing to study the cellular and/or molecular mechanisms involved in said neuropathy, a neuro-cutaneous model obtainable according to said method, and applications thereof.

Abstract: The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.

Abstract: Activated cardiac fibroblasts are essential for the production of extracellular matrix proteins that accumulate during cardiac fibrosis, and PW1+ cardiac adult stem cells were recently proposed as a cellular source of fibroblasts in the ischemic hearts. Here the inventors identify ?V-integrin (or CD51) as an essential regulator of PW1+ cardiac adult stem cells fibrogenic behavior. Inhibition of ?V-integrin reduce the profibrotic gene expression profile and the ability to differentiate into fibroblasts of cardiac PW1+ cells. The pharmacological blockade of ?V-containing integrins improved cardiac function and survival after MI by reducing infarct size and attenuating the extension of reactive cardiac fibrosis. Notably, the total cardiac fibrotic area as well as interstitial fibrosis in the remote myocardial area are significantly reduced after pharmacological blockade of ?V-containing integrins.

Abstract: A method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV) is provided. The method includes steps of: a) performing a depth filtration of a cell lysate or a culture supernatant obtained from cells producing rAAV particles, whereby a rAAV-containing clarified composition is provided; b) submitting the rAAV-containing clarified composition to a first step of anion-exchange chromatography on a chromatographic support wherein the rAAV-containing fraction is collected, whereby a first rAAV enriched composition is provided; c) submitting the first rAAV enriched composition at least once to a second step of anion-exchange chromatography on a chromatographic support wherein the rAAV-containing fraction is collected, whereby a second rAAV enriched composition is provided; d) submitting the second rAAV enriched composition to a step of tangential flow filtration to provide purified recombinant Adeno-Associated Virus particles (rAAV).

Abstract: The present invention relates to a method for identifying a cancer patient presenting microsatellite unstable tumor who is likely to benefit from immunotherapy comprising detecting a mutation within a microsatellite sequence by subjecting said sample to a digital polymerase chain reaction. The present invention also encompasses an immune checkpoint inhibitor for use in the treatment of a cancer in a patient who is previously identified as likely benefit from an immunotherapy and a method for evaluating the therapeutic response of an immune checkpoint inhibitor in a patient having a cancer.

Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Abstract: An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.

Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT??/? Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

Abstract: Compounds of formula (I) or pharmaceutically acceptable salts and/or solvates thereof. Also, the use of the compounds of formula (I) as immunomodulators and in the treatment of autoimmune diseases, transplanted organ rejection, graft-versus-host-disease and BOB1-related diseases, in which the compounds of formula (I) are administered to subjects in need thereof.

Abstract: CD38 is also expressed in a variety of malignant hematological diseases, including multiple myeloma. In the present invention, the inventors have generated a new antibody against CD38 that could be suitable for producing bispecific antibodies as well as CAR-T cells. In particular, the inventors report the development of Bi38-3, a new bispecific T cell engager that targeted CD38 on MM cells and recruited cytotoxic T cells through the CD3?. Bi38-3 lacked the Fc region of natural mAb, which contributes to resistance processes, but triggered T cells to proliferate, release cytokine and lyse CD38 positive MM cells in vitro. Similarly, Bi38-3 induced autologous T cells to eliminate tumor plasma cells isolated from MM patients both at diagnosis and at relapse. The cytotoxicity triggered by Bi38-3 was restricted to cells expressing high levels of CD38 and preserved the integrity of T, B and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in an MM1.S xenograft mouse model of human MM.

Abstract: Methods and systems are provided for decoding movement intentions using functional ultrasound (fUS) imaging of the brain. In one example, decoding movement intentions include determining a memory phase of a cognitive state of the brain, the memory phase between a gaze fixation phase and movement execution phase, and determining one or more movement intentions including one or more of intended effector (e.g., hand, eye) and intended direction (e.g., right, left) according to a machine learning algorithm trained to classify one or more movement intentions simultaneously.

Abstract: A method for treating chronic myelomonocytic leukemia (CMML), or for maintaining or enhancing the proliferation of wildtype hematopoietic stem cells in patients suffering from CMML, by administering to a patient in need thereof a pharmaceutical composition containing an effective amount of an inhibitor of the CXCL8 receptor.

Abstract: Method for estimating a movement of particles in a bone, including the following steps: obtaining data associated with ultrasonic waves emitted at a temporal frequency; obtaining ultrasonic wave phase velocities in the bone in various directions followed by the ultrasonic waves; obtaining videos showing the bone at a point, the videos issuing from ultrasonic waves; computing phase variations at the point between two images of the videos; and computing a particle movement at the point based on the temporal frequency, the data associated with the ultrasonic waves, the phase variations, and the phase velocities in the various directions.

Abstract: Provided herein is a method for detecting a tumour that can be applied to cell-free samples, e.g., to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (e.g., CpG islands, CpG shores, and/or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and/or distribution of tumour signals may be used for tumour detection or classification. The method is also useful in, e.g.

Abstract: Methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides that are or that include epitopes identified by the methods, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with the peptides or vectors and engineered T cells expressing T-cell receptors recognizing the peptides. Also, the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of the peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.

Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.